TNF-alpha inhibitors associated with uveal melanoma
the ONA take:
According to new findings reported in the journal Mayo Clinic Proceedings, researchers warn that there may be a correlation between tumor necrosis factor (TNF)-alpha inhibitors and the development of uveal melanoma.
The researchers report three cases of uveal melanoma that occurred after patients were treated with TNF-alpha inhibitors. Two of the patients were treated at Mayo Clinic in Rochester, Minnesota, and the other was treated at Yale-New Haven Hospital in New Haven, Connecticut. All three, two women and one man, were treated for inflammatory disease with TNF-alpha inhibitors.
This class of drugs include adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab, and they are used to treat inflammatory bowel disease, psoriasis, and rheumatoid arthritis. In the cases reported, the two women were treated for inflammatory bowel disease and developed rapidly growing melanocytic tumors within 1 year of TNF-alpha inhibitor initiation.
The male patient was treated for rheumatoid arthritis and developed a uveal melanoma within 16 months of TNF-alpha inhibitor therapy.
The researchers suggest that there is an association between TNF-alpha inhibitors and cutaneous melanoma and recommend that patients planning to initiate TNF-alpha inhibitor therapy have an eye exam before beginning therapy. If patients have preexisting nevi, they should be monitored with eye examinations at regular intervals during therapy.
There may be a correlation between TNF-alpha inhibitors and the development of uveal melanoma.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Caregiver Mastery Linked to Patient Survival in Glioblastoma
- Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma
- Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|